New combo shows promise in slowing advanced colorectal cancer
NCT ID NCT05945901
First seen Nov 18, 2025 · Last updated Jun 11, 2026 · Updated 33 times
Summary
This study tests whether adding a new drug (HR070803) to standard chemotherapy and targeted therapy can better control advanced colorectal cancer that has spread and cannot be removed by surgery. About 669 adults aged 18-75 who have not had prior treatment for their cancer will receive either the new combo or standard treatment. The goal is to see if the new combo delays cancer growth and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdog, 510060, China
Conditions
Explore the condition pages connected to this study.